Industry View · Life-Science Tools
Life-science tools — the instruments, reagents and sequencers that sit upstream of every drug and diagnostic — is a roughly $154 billion market in 2025 that grew up selling hardware. AI is quietly inverting the value: the molecule of the future is software, the instrument is a data-acquisition front end, and the margin is migrating toward whoever owns the interpretation layer.
Thermo Fisher: AI 30% increase in effective bioproduction capacity; Illumina ~2x diagnostic yield
Protein, DNA and multimodal foundation models now propose targets and structures that wet-lab work used to take years to surface.
Physics-plus-AI platforms and generative chemistry shrink the hit-to-lead cycle, shifting spend from benches to GPUs.
Secondary analysis and variant interpretation, not raw read-out, are where yield and reimbursement are won.
Robotic sample handling plus AI scheduling turn instruments into autonomous, agentic experiment engines.
Recurring data-and-applications revenue is the fastest-growing, highest-multiple layer of the stack.
01 · The thesis
For two decades the tools industry sold razors and blades: a sequencer or mass spectrometer up front, then a perpetual annuity of consumables. AI does not threaten that model so much as relocate its profit pool. When an interpretation algorithm doubles a sequencer's diagnostic yield — Illumina says its PromoterAI, PrimateAI-3D and SpliceAI stack roughly doubles diagnostic yield versus protein-truncating variants alone — the differentiated, defensible asset is the software, not the optics. The hardware risks commoditisation; the model becomes the moat. The clearest tell is who the incumbents are partnering with. Thermo Fisher signed a strategic collaboration with OpenAI and reports AI already delivering a 30% increase in effective capacity at major bioproduction sites. Danaher elevated a former Tempus and Google AI leader to Chief Technology and AI Officer in 2025. Illumina is embedding NVIDIA foundation models into DRAGEN. The competitive question is no longer 'whose box is faster' but 'whose box turns raw signal into an answer a clinician or chemist will pay for.'
Protein, DNA and multimodal foundation models now propose targets and structures that wet-lab work used to take years to surface.
Physics-plus-AI platforms and generative chemistry shrink the hit-to-lead cycle, shifting spend from benches to GPUs.
Secondary analysis and variant interpretation, not raw read-out, are where yield and reimbursement are won.
Robotic sample handling plus AI scheduling turn instruments into autonomous, agentic experiment engines.
Recurring data-and-applications revenue is the fastest-growing, highest-multiple layer of the stack.
02 · The two clocks
The capability clock is fast. AlphaFold 3, released in 2024 by Isomorphic Labs and Google DeepMind, predicts the structure and interactions of all of life's molecules — and Isomorphic raised $600 million in 2025 to push a successor engine toward its first clinical trials by end-2026. The commoditisation clock is the threat to hardware. With >75% of labs planning AI deployment within two years and services the fastest-growing tools segment (~11% CAGR per Mordor), the recurring profit pool is shifting from instruments toward interpretation and data. The regulatory clock is the wildcard. In January 2025 the FDA issued its first draft guidance on AI to support regulatory decision-making across nonclinical, clinical and manufacturing phases — a credibility framework that will decide how fast AI-generated evidence reaches approval.
03 · Public players & exposure
We plot the listed players on two editorial axes — how exposed each is to AI disruption, against how ready its data, brand and position are to be the answer. The figures in the table are sourced; the placement is our read.
04 · Private flagships
The companies attacking this industry AI-first, with disclosed funding where available:
Alphabet's DeepMind spinout aims to design drugs end-to-end from AlphaFold 3, with partnered programs at Eli Lilly and Novartis and internal oncology/immunology work.
Pairs genomic diagnostics with a clinical-molecular data library that pharma licenses; the Ambry Genetics acquisition extended hereditary and rare-disease testing.
Sells computational chemistry software and runs its own AI-designed pipeline, monetising via licenses plus discovery milestones and royalties.
Combines high-throughput automated biology with ML after absorbing Exscientia; reworking its pipeline toward fewer, higher-conviction programs.
The lab-informatics system of record for biotech; the connective software layer where experimental data and AI workflows increasingly converge.
Foundation-model platform and toolkit adopted across genomics and drug discovery, partnering with Illumina, Arc Institute, IQVIA and Mayo Clinic.
05 · Signals
06 · The exposure read
AI rewards clean, structured advantage and punishes friction. The line runs through who owns the data, the brand and the customer — and who is merely a step the technology can route around.
Sources
Where AI revenue and value are concentrating, 2025
Disclosed company figures: Tempus, Agilent, 10x, Schrödinger FY2025 reports; Isomorphic 2025 raise (PRNewswire / Fierce Biotech). ($M (revenue or 2025 funding))
FDA issues first AI draft guidance
Draft guidance on AI to support regulatory decision-making across nonclinical, clinical, post-market and manufacturing — a credibility framework for AI-generated evidence.
Isomorphic raises $600M
Alphabet's drug-design unit takes its first external capital to build a next-gen engine and move AlphaFold-3-designed candidates toward the clinic.
Thermo Fisher partners with OpenAI
The largest tools company embeds OpenAI APIs across product, service and operations, citing 30% effective-capacity gains at bioproduction sites.
Danaher names a CTO and AI Officer
Promotion of an ex-Tempus/Google AI leader plus a Microsoft AI board hire signals a strategic, top-down AI reorientation.
Tempus crosses $1.27B revenue
Diagnostics up ~112% for the year and a $316M data business prove AI-data monetisation at scale in the tools-adjacent layer.
Alphabet's DeepMind spinout aims to design drugs end-to-end from AlphaFold 3, with partnered programs at Eli Lilly and Novartis and internal oncology/immunology work.
Pairs genomic diagnostics with a clinical-molecular data library that pharma licenses; the Ambry Genetics acquisition extended hereditary and rare-disease testing.
Sells computational chemistry software and runs its own AI-designed pipeline, monetising via licenses plus discovery milestones and royalties.
Combines high-throughput automated biology with ML after absorbing Exscientia; reworking its pipeline toward fewer, higher-conviction programs.
The lab-informatics system of record for biotech; the connective software layer where experimental data and AI workflows increasingly converge.
Foundation-model platform and toolkit adopted across genomics and drug discovery, partnering with Illumina, Arc Institute, IQVIA and Mayo Clinic.
| Company | Stance | The sourced fact |
|---|---|---|
| Thermo Fisher Scientific TMO | Scaled incumbent | Reports AI driving a 30% increase in effective capacity at major Pharma services and bioproduction sites, and a strategic OpenAI collaboration embedding its APIs across products and operations. |
| Danaher DHR | AI-native pivot | Elevated Martin Stumpe (ex-Tempus, ex-Google Cancer Pathology) to Chief Technology and AI Officer in 2025, reporting to the CEO, and added Microsoft's AI Copilot VP to its board. |
| Illumina ILMN | Moat in software | Says its AI interpretation stack (PromoterAI, PrimateAI-3D, SpliceAI) roughly doubles diagnostic yield; expanding DRAGEN with NVIDIA Biology foundation models. |
| Tempus AI TEM | Data-first challenger | Generated $1.27B revenue in 2025; its Data and Applications segment alone reached $316.4M, about 25% of total, atop a multimodal oncology dataset. |
| Schrödinger SDGR | Physics + AI | Reported $256M total 2025 revenue with $200M from software; drug-discovery revenue surged 295% in Q3 to $13.5M on collaboration milestones. |
| Agilent A | Automation play | Posted $6.95B FY2025 revenue and is targeting the ~$2B automated-lab market by 2030 with AI-driven LC-MS and GC workflows plus an OmixAI proteomics pact. |
| Recursion RXRX | Burn-rate bet | Post-Exscientia merger ($~688M), full-year pipeline reworked; Q1 2025 revenue was just $15M against a large clinical portfolio, underscoring monetisation risk. |
| 10x Genomics TXG | Volume pressure | FY2025 revenue of $642.8M ($598.7M ex-litigation), a ~2% decline, even as AI-driven demand for single-cell and spatial data rebuilds the pipeline. |
| Bruker BRKR | Multiomics scaler | Targeting ~$3.5B 2025 revenue; building a spatial-biology and functional-proteomics franchise (NanoString CosMx, timsOmni) for the post-genomic era. |
| Isomorphic Labs PRIV | Frontier disruptor | Raised $600M in 2025 (Thrive Capital, GV, Alphabet) to build a next-gen AlphaFold-3-based drug-design engine; first clinical trials guided for end-2026. |